NCT06880146

Cross-validation of a Predictive Model of Response to Anti-TNF Alpha Based on Oxylipin Response in Rheumatoid Arthritis

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: University Hospital, Clermont-Ferrand · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to use a blood test to predict whether a participant diagnosed with rheumatoid arthritis will respond to anti-TNF alpha treatment . The main questions it aims to answer is: Is the predictive model created using oxylipins effective? Participants starting anti-TNF alpha treatment will have a blood sample taken before starting treatment and 6 months afterwards.

Conditions

• Rheumatoid Arthritis

Interventions

Type	Name	Description
OTHER	Blood sample Truculture	blood sample added to the standard blood test at visit Inclusion and Month 6. This project will use the TruCulture® Whole Blood Stimulation System to assess the Whole Blood Oxylipin Response (WBOR). WBOR is the ability of patients to produce oxylipins in response to an immune stimulus. One tube is conditioned with LPS stimulant and a control tube is conditioned with no stimulant (Null).

Timeline

• Start date: 2025-03-15
• Primary completion: 2026-11-01
• Completion: 2027-11-01
• First posted: 2025-03-17
• Last updated: 2025-03-17

Locations

3 sites across 1 country: France